Literature DB >> 23524209

Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project.

Amitava Banerjee1, Laurent Fauchier, Patrick Vourc'h, Christian R Andres, Sophie Taillandier, Jean Michel Halimi, Gregory Y H Lip.   

Abstract

OBJECTIVES: This study sought to determine the risk of ischemic stroke (IS)/thromboembolism (TE) associated with renal impairment and its incremental predictive value over established risk stratification scores (congestive heart failure, hypertension, age ≥75 years, diabetes, previous stroke [CHADS2] and congestive heart failure, hypertension, age ≥75 years, diabetes, previous stroke, vascular disease, age 65 to 74 years, sex category (female) [CHA₂DS₂-VASc]) in patients with atrial fibrillation (AF).
BACKGROUND: Risk stratification schemes for prediction of IS/TE in patients with AF are validated but do not include renal impairment.
METHODS: Patients diagnosed with nonvalvular AF and available estimated glomerular filtration rate (eGFR) data in a 4-hospital institution between 2000 and 2010 were identified. The study population was stratified by renal impairment defined by serum creatinine level and by eGFR measured at time of diagnosis of AF. Independent risk factors of IS/TE (including renal impairment) were investigated in Cox regression models. The incremental predictive value of renal impairment over CHADS₂ and CHA₂DS₂-VASc were assessed with the c-statistic, net reclassification improvement, and integrated discrimination improvement. We focused on the 1-year outcomes in our analyses.
RESULTS: Of 8,962 eligible individuals, 5,912 (66%) had nonvalvular AF and available eGFR data. Renal impairment by both creatinine and eGFR definitions was associated with higher rates of IS/TE at 1 year, compared with normal renal function. After adjustment for CHADS₂ risk factors, renal impairment did not significantly increase the risk of IS/TE at 1 year (hazard ratio: 1.06; 95% confidence interval [CI]: 0.75 to 1.49 for renal impairment; and hazard ratio: 1.09; 95% CI: 0.84 to 1.41 for eGFR). When renal impairment was added to existing risk scoring systems for stroke/TE (CHADS₂ and CHA₂DS₂-VASc), it did not independently add to the predictive value of the scores, whether defined by serum creatinine level or eGFR. This was evident even when the analysis was confined to only those patients with at least 1 year of follow-up.
CONCLUSIONS: Renal impairment was not an independent predictor of IS/TE in patients with AF and did not significantly improve the predictive ability of the CHADS₂ or CHA₂DS₂-VASc scores.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23524209     DOI: 10.1016/j.jacc.2013.02.035

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  32 in total

1.  Impact of renal function deterioration on adverse events during anticoagulation therapy using non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

Authors:  Koji Miyamoto; Takeshi Aiba; Shoji Arihiro; Makoto Watanabe; Yoshihiro Kokubo; Kohei Ishibashi; Sayako Hirose; Mitsuru Wada; Ikutaro Nakajima; Hideo Okamura; Takashi Noda; Kazuyuki Nagatsuka; Teruo Noguchi; Toshihisa Anzai; Satoshi Yasuda; Hisao Ogawa; Shiro Kamakura; Wataru Shimizu; Yoshihiro Miyamoto; Kazunori Toyoda; Kengo Kusano
Journal:  Heart Vessels       Date:  2015-08-15       Impact factor: 2.037

2.  Usefulness of transesophageal echocardiography before cardioversion in atrial arrhythmias.

Authors:  Katarzyna Kosmalska; Małgorzata Rzyman; Paweł Miękus; Natasza Gilis-Malinowska; Radosław Nowak; Marcin Fijałkowski
Journal:  Cardiol J       Date:  2019-06-21       Impact factor: 2.737

3.  Application of net reclassification index to non-nested and point-based risk prediction models: a review.

Authors:  Laine E Thomas; Emily C O'Brien; Jonathan P Piccini; Ralph B D'Agostino; Michael J Pencina
Journal:  Eur Heart J       Date:  2019-06-14       Impact factor: 29.983

4.  Renal function assessment in atrial fibrillation: Usefulness of chronic kidney disease epidemiology collaboration vs re-expressed 4 variable modification of diet in renal disease.

Authors:  Rami Riziq-Yousef Abumuaileq; Emad Abu-Assi; Andrea López-López; Sergio Raposeiras-Roubin; Moisés Rodríguez-Mañero; Luis Martínez-Sande; Francisco Javier García-Seara; Xesus Alberte Fernandez-López; Jose Ramón González-Juanatey
Journal:  World J Cardiol       Date:  2015-10-26

Review 5.  Stratifying Stroke Risk in Atrial Fibrillation: Beyond Clinical Risk Scores.

Authors:  Shadi Yaghi; Hooman Kamel
Journal:  Stroke       Date:  2017-09-15       Impact factor: 7.914

Review 6.  Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction.

Authors:  Tatjana S Potpara; Charles J Ferro; Gregory Y H Lip
Journal:  Nat Rev Nephrol       Date:  2018-03-26       Impact factor: 28.314

Review 7.  Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Con.

Authors:  Vaibhav Keskar; Manish M Sood
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-25       Impact factor: 8.237

8.  Performance of the Cockcroft-Gault, MDRD and CKD-EPI Formulae in Non-Valvular Atrial Fibrillation: Which one Should be Used for Risk Stratification?

Authors:  Sérgio Barra; Rui Providência; Catarina Faustino; Luís Paiva; Andreia Fernandes; António Leitão Marques
Journal:  J Atr Fibrillation       Date:  2013-10-31

Review 9.  Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation.

Authors:  Gunnar H Heine; Vincent Brandenburg; Stephan H Schirmer
Journal:  Dtsch Arztebl Int       Date:  2018-04-27       Impact factor: 5.594

10.  Prognosis in patients with atrial fibrillation and a presumed "temporary cause" in a community-based cohort study.

Authors:  Laurent Fauchier; Nicolas Clementy; Arnaud Bisson; Karim Stamboul; Fabrice Ivanes; Denis Angoulvant; Dominique Babuty; Gregory Y H Lip
Journal:  Clin Res Cardiol       Date:  2016-09-30       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.